b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM">\n        <PMID Version="1">31218504</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>06</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>01</Month>\n            <Day>08</Day>\n        </DateRevised>\n        <Article PubModel="Print">\n            <Journal>\n                <ISSN IssnType="Print">0070-217X</ISSN>\n                <JournalIssue CitedMedium="Print">\n                    <Volume>424</Volume>\n                    <PubDate>\n                        <Year>2019</Year>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Current topics in microbiology and immunology</Title>\n                <ISOAbbreviation>Curr. Top. Microbiol. Immunol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Artemisinin-Resistant Malaria as a Global Catastrophic Biological Threat.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>33-57</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1007/82_2019_163</ELocationID>\n            <Abstract>\n                <AbstractText>The global spread of artemisinin resistance brings with it the threat of incurable malaria. Already, this disease threatens over 219 million lives per year and causes 5-6% losses in GDP in endemic areas, even with current advances in prevention and treatment. This chapter discusses the currently tenuous position we are in globally, and the impact that could be seen if artemisinin treatment is lost, whether due to the unchecked spread of K13 mutations or poor global investment in treatment and prevention advances. Artemisinin is the backbone of current ACT treatment programs and severe malarial treatment; without it, the success of future malaria eradication programs will be in jeopardy.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ricotta</LastName>\n                    <ForeName>Emily</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Quarters 15B-1, 8 West Dr, Bethesda, MD, 20892, USA. emily.ricotta@nih.gov.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Kelly Government Solutions, Bethesda, USA. emily.ricotta@nih.gov.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Kwan</LastName>\n                    <ForeName>Jennifer</ForeName>\n                    <Initials>J</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Quarters 15B-1, 8 West Dr, Bethesda, MD, 20892, USA.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>Germany</Country>\n            <MedlineTA>Curr Top Microbiol Immunol</MedlineTA>\n            <NlmUniqueID>0110513</NlmUniqueID>\n            <ISSNLinking>0070-217X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D037621">Artemisinins</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D037621" MajorTopicYN="N">Artemisinins</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004351" MajorTopicYN="N">Drug Resistance</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D062665" MajorTopicYN="Y">Epidemiological Monitoring</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016778" MajorTopicYN="N">Malaria, Falciparum</DescriptorName>\n                <QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>\n                <QualifierName UI="Q000469" MajorTopicYN="Y">parasitology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010963" MajorTopicYN="N">Plasmodium falciparum</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n                <QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>18</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>6</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31218504</ArticleId>\n            <ArticleId IdType="doi">10.1007/82_2019_163</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'